This database contains 536 studies, archived under the term: "psychology"
Click here to filter this large number of results.
The peaceful mind program: a pilot test of a cognitive-behavioral therapy-based intervention for anxious patients with dementia
Stanley, Melinda A.,
Calleo, Jessica,
Bush, Amber L.,
Wilson, Nancy,
Snow, A. Lynn,
Kraus-Schuman, Cynthia,
Paukert, Amber L.,
Petersen, Nancy J.,
Brenes, Gretchen A.,
Schulz, Paul E.,
Williams, Susan P.,
Kunik, Mark E.
Objectives: To assess feasibility and to conduct a preliminary evaluation of outcomes following Peaceful Mind, a cognitive-behavioral therapy-based intervention for anxiety in dementia, relative to usual care.; Design: Pilot randomized controlled trial including assessments at baseline and 3 and 6 months.; Setting: Houston, TX.; Participants: Thirty-two outpatients diagnosed with mild (47%) or moderate (53%) dementia […]
Influence of adherence to a systematic care program for caregivers of dementia patients
Spijker, Anouk,
Teerenstra, Steven,
Wollersheim, Hub,
Adang, Eddy,
Verhey, Frans,
Vernooij-Dassen, Myrra
Objective: To evaluate the influence of adherence to the Systematic Care Program for Dementia (SCPD) intervention protocol on patient and caregiver outcomes.; Design: Data were drawn from the SCPD study-a single-blind, multicenter, cluster-randomized, controlled trial. Multivariate regression analyses were used to assess the influence of adherence on patient and caregiver outcomes.; Setting: Six community mental health […]
Angiotensin-converting enzyme inhibitors and Alzheimer’s disease progression in older adults: results from the Réseau sur la Maladie d’Alzheimer Français cohort
Soto, Maria E.,
Abellan van Kan, Gabor,
Nourhashemi, Fati,
Gillette-Guyonnet, Sophie,
Cesari, Matteo,
Cantet, Christelle,
Rolland, Yves,
Vellas, Bruno
Objectives: To assess whether angiotensin-converting enzyme inhibitor (ACE-I) treatment is associated with less cognitive decline in older adults with Alzheimer’s disease (AD) than in those using other hypertensive or no drugs.; Design: Four-year prospective multicenter cohort study with a biannual assessment.; Setting: Memory clinics from 16 university hospitals in France.; Participants: Community-dwelling older adults with […]
Assessment of cognition in mild cognitive impairment: a comparative study
Snyder, Peter J.,
Jackson, Colleen E.,
Petersen, Ronald C.,
Khachaturian, Ara S.,
Kaye, Jeffrey,
Albert, Marilyn S.,
Weintraub, Sandra
The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer’s disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective […]
The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene
Snowden, Julie S.,
Hu, Quan,
Rollinson, Sara,
Halliwell, Nicola,
Robinson, Andrew,
Davidson, Yvonne S.,
Momeni, Parastoo,
Baborie, Atik,
Griffiths, Timothy D.,
Jaros, Evelyn,
Perry, Robert H.,
Richardson, Anna,
Pickering-Brown, Stuart M.,
Neary, David,
Mann, David M. A.
Frontotemporal lobar degeneration (FTLD) is clinically, pathologically and genetically heterogeneous. Recent descriptions of a pathological sub-type that is ubiquitin positive, TDP-43 negative and immunostains positive for the Fused in Sarcoma protein (FUS) raises the question whether it is associated with a distinct clinical phenotype identifiable on clinical grounds, and whether mutations in the Fused in […]